Core Viewpoint - Gaoguang Pharmaceutical has submitted an application to list on the Hong Kong Stock Exchange, focusing on drug development for autoimmune/inflammatory diseases and neuroinflammation, including Alzheimer's and Parkinson's diseases [1] Company Overview - Gaoguang Pharmaceutical is co-sponsored by China International Capital Corporation and CMB International [1] - The company possesses end-to-end capabilities from target selection to clinical development, with a differentiated asset portfolio that includes four clinical-stage and multiple preclinical-stage candidates [1] Key Products - The core product TLL-018, along with TLL-041 and TLL-009, is the world's only highly selective TYK2/JAK1 inhibitor, expected to be a first-in-class and best-in-class therapy for chronic spontaneous urticaria (CSU) and rheumatoid arthritis (RA) [1] - TLL-018 is currently undergoing two Phase III registration trials for CSU and RA in China, with plans to submit a New Drug Application (NDA) to the National Medical Products Administration by the end of 2026 [1]